Time for a good run4 Sep 2025 07:30
Very encouraging rns explains all the buying recently
We now have a tractable formulation for both animal and human use and our second toxicology species, as required by regulatory authorities, has been confirmed by new data showing appropriate handling of our Ox-1 lead compound in blood following oral administration.
"We anticipate updating the market over the coming weeks and months on further substantial progress. This will include completion of the 0.5 and 10kg scale manufacturing campaigns, further dose range finding studies to enable the initiation of the toxicology studies and the start and finish of the regulatory standard 28-day toxicology studies. We will also provide updates on the manufacture of bulk and capsule material to a standard acceptable for human administration, along with our interactions with appropriate regulatory agencies in preparation for our clinical trial application.
"In short, with this substantial recent progress we remain confident that we are on target to achieve the data required to support a clinical trial submission for this exciting programme according to the plan we have outlined."